Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 26 May 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Immunochemical fecal occult blood test detects cancer

A 3-sample immunochemical test measuring the hemoglobin content of stool samples has good success rates in identifying colorectal cancer, reports the Annals of Internal Medicine issue this week.

News image

fiogf49gjkf04

Guaiac-based fecal occult blood tests for colorectal cancer screening are not specific for human hemoglobin and have low sensitivity.

Automated-development, immunochemical guaiac-based fecal occult blood tests are quality-controlled, and are specific for human haemoglobin.

The tests do not require diet restriction.

Dr Paul Rozen and colleagues from Israel measured the sensitivity and specificity of immunochemical fecal hemoglobin measurements in detecting cancer with colonoscopy.

The research team determined fecal hemoglobin thresholds that give the highest post-test probability for neoplasia.

The researchers also determined the number of immunochemical Guaiac-based fecal occult blood tests needed.

The sensitivity of the test for cancer was 94%
Annals of Internal Medicine

The researchers undertook a prospective, cross-sectional study in ambulatory endoscopy services.

The team evaluated 1000 consecutive ambulatory patients.

Some of the patients were asymptomatic but at increased risk for colorectal neoplasia.

The symptomatic patients underwent elective colonoscopy, and volunteered to prepare immunochemical guaiac-based fecal occult blood tests.

The hemoglobin content of 3 bowel movements was measured.

The team compared the highest value with colonoscopy findings.

Sensitivity, specificity, and predictive values were calculated.

The researchers measured likelihood ratios, and 95% confidence intervals of fecal hemoglobin measurements for clinically significant neoplasia.

The team assessed the relationship of these outcomes to the amount of fecal hemoglobin measured, and the number of immunochemical tests performed.

The researchers found that colonoscopy identified clinically significant neoplasia in 91 patients.

Colonoscopy identified cancer in 17 patients, and advanced adenomas in 74 patients.

Using 3 immunochemical guaiac-based fecal occult blood tests and a hemoglobin threshold of 75 ng/mL of buffer, sensitivity and specificity were 94% and 88%, respectively, for cancer.

The team found that the sensitivity and specificity for significant neoplasia was 67% and 91%, respectively.

The team reported that some patients were tested while discontinuing aspirin and anticoagulant therapies.

In addition, the team highlighted that study patients were at increased risk, and the results may not apply to average-risk populations.

Dr Rozen's team concludes, “Quantitative immunochemical guaiac-based fecal occult blood tests have good sensitivity and specificity for detection of clinically significant neoplasia.”

“Test performance in screening average-risk populations is not known.”

Ann Int Med 2007: 146(4): 244-55
21 February 2007

Go to top of page Email this page Email this page to a colleague

 25 May 2018 
Colorectal cancer–specific mortality
 25 May 2018 
Technology to increase colorectal cancer screening
 25 May 2018 
Post‐operative complications in elderly IBD
 24 May 2018 
Patient-reported outcome measures in IBD trials
 24 May 2018 
Alcohol consumption and outcomes in drug-induced liver injury
 24 May 2018 
Precision medicine for tumors
 23 May 2018 
Management of perianal fistulas in Crohn’s disease
 23 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 23 May 2018 
High body mass index is and ulcerative colitis
 22 May 2018 
Worldwide H.pylori prevalence
 22 May 2018 
PPI and risk of stroke
 22 May 2018 
Online tool predicts bowel dysfunction severity prior to anterior resection
 21 May 2018 
Depressive symptoms in IBD youth
 21 May 2018 
PPI use and cognitive decline
 21 May 2018 
Fecal incontinence and quality of life in IBD
 18 May 2018 
Esophageal dilatation in clinical practice 
 17 May 2018 
IBD and later extraintestinal manifestations
 17 May 2018 
Repeat stool DNA testing
 17 May 2018 
IBS and chronic fatigue following GI infection
 16 May 2018 
Factors associated with fecal incontinence
 16 May 2018 
Diagnostic delay in Crohn's disease
 16 May 2018 
Cardiovascular risk in diabetes mellitus with NAFLD
 15 May 2018 
Guidelines for management of Crohn's
 15 May 2018 
Hep B in the Grey Zone
 15 May 2018 
New therapies for CDI
 14 May 2018 
Blood test for the diagnosis of fibrotic NASH
 14 May 2018 
Outcomes at bariatric centers of excellence
 14 May 2018 
Management of perianal fistulas in Crohn’s
 11 May 2018 
Detection of undiagnosed celiac disease
 11 May 2018 
Alcohol consumption and drug-induced liver injury
 10 May 2018 
Colorectal cancer screening
 10 May 2018 
Fibrosis in patients with chronic hepatitis B
 09 May 2018 
Fecal incontinence
 09 May 2018 
Health problems and IBS
 09 May 2018 
Esophageal dilatation in clinical practice 
 07 May 2018 
Omitting antibiotics in uncomplicated acute diverticulitis
 07 May 2018 
Health problems and IBS
 07 May 2018 
Assessment of diminutive colorectal polyps
 04 May 2018 
National Institutes of Health workshop and obesity
 04 May 2018 
Factors associated with fecal incontinence
 04 May 2018 
Colorectal cancer screening and ethnic inequities
 03 May 2018 
Gastrointestinal ultrasound in IBD
 03 May 2018 
Ultransonography in postsurgical recurrence in Crohn's
 02 May 2018 
Symptom assessment in cirrhotic ascites
 02 May 2018 
Hep C antiviral treatment and liver cancer risk
 02 May 2018 
Chronic Hep B
 01 May 2018 
European guidelines on pancreatic cystic neoplasms
 01 May 2018 
Interferon‐free regimens in Hep C
 01 May 2018 
Age at IBD onset and extraintestinal complications
 30 April 2018 
Formula for preterm infants
 30 April 2018 
Primary antibiotic resistance and sequential therapy for H. pylori
 27 April 2018 
Eastern and western practices for endoscopic resection of colorectal lesions
 27 April 2018 
Anxiety scale for chronic esophageal disease
 27 April 2018 
Disease activity in eosinophilic esophagitis
 26 April 2018 
Obesity and physical activity in diverticulosis
 26 April 2018 
Primary sclerosing cholangitis in the USA
 25 April 2018 
Aspirin and pancreatic cancer
 25 April 2018 
Central mediators of irinotecan-induced steatohepatitis
 25 April 2018 
Neuroimaging in Hep C
 24 April 2018 
Scoring system identifies cancer risk in Barrett's

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us